Multiple antigenic peptide against corona virus and immunostimulating composition containing the same

1 . A multiple antigen peptide comprising four to eight peptides, each peptide consisting of an amino acid sequence of a coronavirus spike protein consisting of 11 consecutive amino acids set forth in SEQ ID NO: 7.

2 . The multiple antigen peptide according to claim 1 , wherein the amino acid sequence set forth in SEQ ID NO: 7 is SEQ ID NO: 1, 2, 6, or 8.

3 . The multiple antigen peptide according to claim 1 , comprising a dendritic polymer backbone and a peptide, wherein the peptide is linked to a tail end of the dendritic polymer backbone.

4 . The multiple antigen peptide according to claim 3 , wherein the dendritic polymer backbone and the peptide are linked via a linker to each other.

5 . The multiple antigen peptide according to claim 3 , wherein, in the dendritic polymer backbone, to each of 2 amino groups of a lysine residue, a lysine residue forming a first-generation branch is bound via a peptide bond; and to each of 4 amino groups of the lysine residues forming a first-generation branch thus formed, a peptide is linked with or without a linker.

6 . The multiple antigen peptide according to claim 3 , wherein, in the dendritic polymer backbone, to each of 2 amino groups of a lysine residue, a lysine residue forming a first-generation branch is bound via a peptide bond; to each of 4 amino groups of the lysine residue forming the first-generation branch, a lysine reside forming a second-generation branch is bound via a peptide bond; and to each of 5 or more, 6 or more, 7 or more or 8 or more amino groups of the lysine residues forming a second-generation branch thus formed, a peptide is linked with or without a linker.

7 . The multiple antigen peptide according to claim 1 , having the following formula (VI):

wherein R represents-linker-peptide or -peptide, the peptide is the peptide according to any one of claims 1 to 5 ; R 2 represents a hydrogen atom, an OH group, a substituted or unsubstituted lower alkyl group, an amino group, an amino acid, a halogen atom or a peptide; and the amino acid is linked to the above molecule via an amide bond.

8 . A vaccine against a coronavirus, comprising the multiple antigen peptide according to claim 1 .

9 . The vaccine according to claim 8 , comprising no adjuvants.

10 . The vaccine according to claim 8 , wherein the coronavirus is SARS-CoV-2 or a mutant virus thereof.

11 . The vaccine according to claim 8 , wherein the coronavirus is one or more coronaviruses selected from porcine epidemic diarrhea virus (PED), canine coronavirus and feline infectious peritonitis virus (FIPV).

12 . A pharmaceutical composition comprising the multiple antigen peptide according to claim 1 .

13 . A method for administering a peptide to a subject, comprising administering an effective amount of the pharmaceutical composition according to claim 12 to the subject.

14 . A method comprising administering an effective amount of the pharmaceutical composition according to claim 12 to a subject, wherein the method

(a) activates immunity against a coronavirus in the subject;

(b) induces antigen-specific immunity against a coronavirus in the subject;

(c) induces an antigen-specific IgM antibody against a coronavirus in the subject;

(d) induces formation of immunological memory against a corona virus in the subject; and/or

(e) prevents and/or treats an infection with a coronavirus in the subject.

15 . The multiple antigen peptide according to claim 1 , wherein at least one of the peptides consists of the amino acid sequence set forth in SEQ ID NO: 1.

16 . The multiple antigen peptide according to claim 1 , wherein at least one of the peptides consists of the amino acid sequence set forth in SEQ ID NO: 6.

17 . The multiple antigen peptide according to claim 1 , wherein at least one of the peptides consists of the amino acid sequence set forth in SEQ ID NO: 8.